The long-term holders of Riverstone are now thrilled at seeing the stock hit $2.40. There are some core metrics of Riverstone's dynamics that apply to Medtecs, imo. The 2Q profit of Medtecs should reflect :
1. Ramp-up in revenue
2. Higher ASP.
3. Most important: Higher operating leverage leading to much higher profit margin. Therefore, net profit will be much higher than 1Q US$3.7 million. Dyodd
Is it too early to say Riverstone has peaked, can't go higher, than $3.00?
I guess not. The latest target price of DBS is $3.90, and my guess is it will be revised higher when the 2Q results come out & give clarity to the near- and medium-term outlook. Already, DBS reported that Riverstone's orderbook is full all the way until mid-2021. I won't be surprised if Riverstone goes above $4.00! dyodd